Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGLT2 Inhibitors for Cardioprotection in Heart Transplant
NCT06147271Phase 2Enrolling by invitation
- Sponsor
- Federal University of Ceará
- Start
- Nov 2023
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dapagliflozin, empagliflozin in cardiac allograft vasculopathy (CAV), sponsored by Federal University of Ceará. Started Nov 2023; status: enrolling by invitation.
02
Drugs
dapagliflozinempagliflozin
03
Conditions
cardiac allograft vasculopathy (CAV)
Beyond the preview
Go deeper on NCT06147271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06147271.